Health literacy is not only the degree to which individuals can obtain and understand basic health information, but also includes their ability to act on that information to make informed health decisions ([@B1]). Lower levels of health literacy, and in particular reading ability, have been associated with a high prevalence of adverse health outcomes because of an inadequate use of health care services ([@B2]--[@B6]). In the context of type 2 diabetes, the impact of health literacy on health outcomes is not fully understood. The American Diabetes Association (ADA) continues to recommend that physicians prescribe self-monitoring of blood glucose (SMBG) to patients with noninsulin-treated type 2 diabetes, because SMBG is associated with meeting A1C targets ([@B7],[@B8]). However, for SMBG to be useful, the ADA recommends integrating glucose values into clinical and self-management plans ([@B8]). Our study aimed to explore the association between patient health literacy and patient-reported outcomes such as numeracy of SMBG use, how often physicians advised patients to conduct SMBG testing, and the clinical outcome of glycemic control as measured by A1C in patients with noninsulin-treated type 2 diabetes.

Research Design and Methods {#s1}
===========================

Participants and Measures {#s2}
-------------------------

This study used baseline data obtained from a parent study investigating whether SMBG testing in patients with noninsulin-treated type 2 diabetes and varying baseline characteristics led to improvements in patient-reported and clinical outcomes over time ([@B9]). In the parent study, there was no significant difference in glycemic control at 1 year between patients who performed once-daily SMBG and those who did not perform SMBG. Given the results, we examined the role of patient health literacy in overall glycemic control and SMBG usage ([@B9]). Our study population included 448 patients with noninsulin-treated type 2 diabetes who attended one of 15 University of North Carolina Health Care--associated primary care practices (family and internal medicine) located within central North Carolina. Eligible patients were ≥30 years of age and had an A1C level between 6.5 and 9.5% within 6 months preceding enrollment. Patients were excluded if they planned to see an endocrinologist within the next 12 months or if they planned to use insulin during the study period. The Newest Vital Sign (NVS) screening tool was used to assess health literacy in our patient population instead of other traditional tools for measuring health literacy. The NVS is easily administered in 3 minutes and is a research tool that uses a patient's ability to read and analyze a nutritional label to test prose literacy, numeracy, and document literacy ([@B10]). The NVS scores range from 0 to 6, with higher scores (≥4) associated with adequate health literacy ([@B11]). At baseline, all study participants were asked whether they currently use SMBG. If SMBG was used, participants indicated both how often they tested and how often they were told to test by their personal primary care physician. A1C levels were measured using venous blood draws and standard laboratory processing procedures.

Data Collection {#s3}
---------------

Demographic, socioeconomic, and clinical characteristics were collected from baseline interviews with each patient.

Statistical Analysis {#s4}
--------------------

Data analysis was conducted on all 448 participants who had completed all baseline assessments. Wilcoxon rank sum and χ^2^ tests were used to assess the mean difference in glycemic control, patient-reported frequency of SMBG testing, and how often physicians advised patients to conduct SMBG testing between patients with limited and adequate health literacy. NVS scores were dichotomized using the previously reported cutoff point of 4 to determine patient health literacy (≥4 indicates adequate health literacy) ([@B7]).

Results {#s5}
=======

[Table 1](#T1){ref-type="table"} summarizes the demographic, socioeconomic, and clinical data obtained from each participant. Participants were relatively well-educated individuals, mostly married, and the majority female (54.0%), with an average age of 60.5 years. The mean A1C level of all respondents was 7.6% (±1.1%). A total of 38.2% of participants was determined to have limited health literacy. Participants with limited health literacy had significantly poorer glycemic control than participants with adequate health literacy (A1C 7.7 ± 1.1% vs. 7.5 ± 1.0%, *P* = 0.016).

###### 

Summary of Demographic and Clinical Data for All Participants With Limited Versus Adequate Health Literacy (*n* = 448)

  Characteristic                                     Health Literacy       
  -------------------------------------------------- --------------------- ---------------------
  Age, years, mean (min, max)                        64.3 (31, 92)         58.1 (32, 85)
  Male, *n* (%)                                      86 (50.3)             121 (43.7)
  Race, *n* (%)                                                            
   White                                             85 (49.7)             193 (69.7)
   Black or African American                         74 (43.3)             73 (26.4)
   Other                                             12 (7.0)              11 (4.0)
  Education, *n* (%)                                                       
   Less than high school                             20 (11.7)             5 (1.8)
   High school graduate/some college                 127 (74.3)            142 (51.4)
   College graduate or more                          24 (14.0)             129 (46.7)
  Marital status, *n* (%)                                                  
   Married/living together                           106 (62.0)            189 (68.2)
   Not married/living together                       65 (38.0)             88 (31.8)
  Number of comorbidities, mean (min, max)           3.7 (0, 10)           3.2 (0, 8)
  Type 2 diabetes duration, years, mean (min, max)   9.2 (0, 44)           7.6 (0, 50)
  BMI, kg/m^2^, mean (min, max)                      32.8 (21, 57)         35.2 (21, 75)
  A1C, %, mean (min, max)                            7.7 ([@B6], [@B13])   7.5 ([@B6], [@B13])
  Current use of SMBG testing, *n* (%)                                     
   Yes                                               134 (78.4)            202 (72.9)
   No                                                37 (21.6)             75 (27.1)

Limited health literacy defined as \<4 on NVS assessment tool.

[Table 2](#T2){ref-type="table"} illustrates the frequency of SMBG testing completed by patients and how often patients were told to test by their physicians. The results are labeled as once daily, intermittently (not daily, but one or more times per week), and rarely (less than one time per week). Of the participants who were currently performing SMBG testing (*n* = 336), 55.7% had been told by their physicians to perform once-daily SMBG testing. There was no statistically significant difference in the frequency of which physicians told their patients to conduct SMBG testing between limited and adequate health literacy groups (*P* = 0.68) ([Table 2](#T2){ref-type="table"}). Of the participants who did not partake in SMBG testing (*n* = 112), 44.6% reported not doing so because they had not been advised by their physicians to test; and 16.1, 7.1, and 6.25% did not do so because of cost, pain associated with testing, and not understanding the benefits of testing, respectively.

###### 

Comparison of Physician-Advised and Self-Reported SMBG Use in Patients With Limited Versus Adequate Health Literacy in Individuals Currently Using SMBG Testing (*n* = 336)

  Outcome                             Health Literacy                
  ----------------------------------- ----------------- ------------ -------
  Current frequency of SMBG testing                                  0.001
   Once daily                         66 (49.3)         62 (30.7)    
   Intermittently                     58 (43.2)         109 (54.0)   
   Rarely                             10 (7.5)          31 (15.3)    
  How often told to SMBG test                                        0.682
   Once daily                         80 (59.7)         106 (53.0)   
   Intermittently                     24 (17.9)         43 (21.5)    
   Rarely                             2 (1.5)           3 (1.5)      
   Not sure                           28 (20.9)         48 (24.0)    

Significantly more patients with limited health literacy performed once-daily SMBG testing significantly (once-daily SMBG testing 49.3 vs. 30.7%, *P* = 0.001) compared to individuals with adequate health literacy ([Table 2](#T2){ref-type="table"}).

Conclusion {#s6}
==========

Despite prior research indicating the unclear usefulness and cost-effectiveness of SMBG in patients with noninsulin-treated type 2 diabetes, this study illustrates that a majority (55.7%) of physicians who advise their patients to undergo SMBG testing advise them to test once daily. Despite most patients receiving the recommendation to conduct once-daily SMBG testing, 29.45% of patients who were not currently testing did not do so because of the cost of testing materials, the pain associated with testing, or their lack of understanding regarding the benefits of testing. This result aligns with research that indicates SMBG being useful and cost-effective only in patients who can incorporate their SMBG values in their diabetes care plan and treatment goals ([@B12]).

There was no significant difference in how often patients with noninsulin-treated type 2 diabetes and limited or adequate health literacy were told by their physicians to conduct SMBG testing. Regardless of each patient's health literacy status, the majority of physicians advised their patients to perform once-daily SMBG testing. The need for individualized diabetes treatment plans has previously been called into question by research that determined that personal blood glucose testing patterns were frequently omitted by physicians and that many patients experience difficulty undertaking lifestyle changes (i.e., diet and exercise) based on the results of their regular SMBG testing ([@B13]). This study adds to the discussion regarding whether more individualized treatment plans can be used to aid patients in achieving better glycemic control and a higher quality of life.

There were several limitations to our study and data analysis. One-on-one patient interviews and questionnaires were used to obtain patient-reported outcomes, including frequency of SMBG testing and how often physicians told their patients to conduct SMBG testing. Medical records were not used to determine the frequency of SMBG testing assigned by each patient's physician, which introduces the potential for recall bias. Furthermore, the reasons for increased frequency of SMBG testing in patients with limited health literacy were not examined in this study.

In the context of patient A1C levels, our study adds to previous research that has found a decreased level of glycemic control in patients with limited health literacy ([@B14],[@B15]). Patients with limited health literacy have a decreased degree of glycemic control despite using SMBG testing significantly more often than individuals with adequate health literacy. This finding is paradoxical because numeracy of SMBG use is a measure of diabetes self-care, which is generally associated with better glycemic control. A decreased level of glycemic control despite using SMBG testing more often in patients with limited health literacy demonstrates the need for more rigorous patient education to ensure patients understand the true benefit of using SMBG testing and what can be done to manipulate their obtained blood glucose levels. In addition, avoiding unnecessary SMBG testing can reduce the pain and costs involved with routine SMBG testing, therefore minimizing the barriers involved with proper testing at times of necessity.
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